Epigral Limited has submitted the Annual Report of F.Y. 2025-26.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral Limited submitted its FY 2025-26 Annual Report and announced its 19th AGM scheduled for June 8, 2026 via video conferencing. The company reported revenue of Rs 2,542 crore (down 1%) and EBITDA of Rs 567 crore (down 20%) due to pricing pressure, a major maintenance shutdown, and subdued downstream demand. Net profit stood at Rs 333 crore (including Rs 81 crore deferred tax benefit; excluding this, PAT would be Rs 252 crore). The company maintained a strong Balance Sheet with net worth of Rs 2,221 crore, net debt/EBITDA at 0.9x, and CRISIL AA/Stable rating. Key expansions are on track: CPVC capacity doubling to 150,000 TPA and ECH capacity to 100,000 TPA, both targeted for Q2 FY 2026-27. The company fixed June 1, 2026 as record date for dividend entitlement. Derivatives and specialty business now contributes 52% of revenues, targeting over 70% by FY 2027-28.
Despite a challenging year with margin compression, Epigral demonstrated Balance Sheet resilience with conservative leverage (0.2x debt-equity) and continued capex deployment. The upcoming expansions and increasing specialty mix position the company for volume-driven growth as market conditions improve. Dividend and e-voting details provide clarity for shareholders ahead of the AGM.